Kevin R. Lind

2023 - Longboard Pharmaceuticals

In 2023, Kevin R. Lind earned a total compensation of $2.1M as President and Chief Executive Officer at Longboard Pharmaceuticals, a 36% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$442,860
Option Awards$986,934
Salary$610,000
Other$14,010
Total$2,053,804

Lind received $986.9K in option awards, accounting for 48% of the total pay in 2023.

Lind also received $442.9K in non-equity incentive plan, $610K in salary and $14K in other compensation.

Rankings

In 2023, Kevin R. Lind's compensation ranked 503rd out of 2,918 executives tracked by ExecPay. In other words, Lind earned more than 82.8% of executives.

ClassificationRankingPercentile
All
503
out of 2,918
83rd
Division
Manufacturing
290
out of 1,608
82nd
Major group
Chemicals And Allied Products
201
out of 901
78th
Industry group
Drugs
198
out of 864
77th
Industry
Pharmaceutical Preparations
125
out of 622
80th
Source: SEC filing on April 12, 2024.

Lind's colleagues

We found two more compensation records of executives who worked with Kevin R. Lind at Longboard Pharmaceuticals in 2023.

2023

Randall Kaye

Longboard Pharmaceuticals

Chief Medical Officer

2023

Brandi Roberts

Longboard Pharmaceuticals

Chief Financial Officer

News

You may also like